Introduction
Interleukin-3 (IL-3), also referred to as multipotential colony-stimulating factor, acts on a wide range of hematopoietic cells including hematopoietic stem/progenitors, macrophages, megakaryocytes, neutrophils, and mast cells. Its essential role in regulating hematopoietic cell survival, proliferation, and differentiation has been well documented. In the mouse, IL-3 exerts its function by binding to two distinct high-affinity receptors composed of a ligand-specific a subunit (IL-3 Ra) and one of two b subunits (IL-3 Rb): an IL-3-specific b chain (Aic2A) or a common b chain (Aic2B) that is shared among the receptors for IL-3, granulocyte macrophage colony-stimulating factor (GM-CSF), and IL-5. Upon binding by IL-3, its receptors heterodimerize and become quickly tyrosyl phosphorylated. Activated receptors, in particular the common receptor b chains, then trigger a signal relay to the targets in the nucleus to induce cellular responses through shared downstream pathways such as the Jak-Stat, Ras-Raf-MAP, and PI3 kinase pathways (Okuda et al., 1999; Reddy et al., 2000) .
Although IL-3-triggered signal transduction has been extensively investigated, the precise regulation of its pathways is still not well understood. Upon receptor engagement by IL-3, nonreceptor tyrosine kinases such as Jak2 and Src family members are activated (Okuda et al., 1999; Reddy et al., 2000) . Activated Jak2 and/or Src family kinases in turn phosphorylate the receptor b chains on multiple tyrosine residues, which thereafter serve as docking sites for other Src homology (SH) 2 or phosphotyrosine binding domain-containing signaling molecules such as the Shc adaptor protein to induce activation of downstream signaling pathways (Pratt et al., 1996; Bone and Welham, 2000; Gu et al., 2000) . Jak2 has been demonstrated to play a central role in receptor b chain signaling (Watanabe et al., 1996) . Jak2 deficiency abrogates biological and biochemical responses to IL-3 or GM-CSF in hematopoietic cells (Neubauer et al., 1998; Parganas et al., 1998) . However, as the signaling b chains do not possess intrinsic catalytic activity, the molecular mechanisms of Jak2 activation and the signaling components involved in this process remain largely unknown.
SHP-2, an SH2 domain-containing protein tyrosine phosphatase, is ubiquitously expressed in a variety of tissues and cell types, and has been implicated in diverse signaling pathways, including those initiated by growth factors, cytokines, insulin, and interferons (Tonks and Neel, 2001; Qu, 2002) . A large body of evidence has demonstrated that, in most circumstances, SHP-2 plays a positive role in transducing the signal relay elicited from receptor tyrosine kinases such as EGF and FGF receptors (Tang et al., 1995; Bennett et al., 1996; Hadari et al., 1998; Shi et al., 1998) . This phosphatase is also highly expressed in hematopoietic cells and has been indicated to be involved in signal transduction of a number of hematopoietic growth factors, including IL-3 (Welham et al., 1994; Gu et al., 1998) . Upon IL-3 stimulation, SHP-2 binds via its N-terminal SH2 domain to tyrosyl-phosphorylated receptor b chain. It also interacts with downstream signaling molecules (Bone et al., 1997; Itoh et al., 1998; Gu et al., 2000) . However, it is not clear exactly how SHP-2 functions in IL-3-triggered signal transduction, due to lack of an SHP-2 deficient hematopoietic cell line. An essential role for SHP-2 in regulating the onset of hematopoietic development has recently emerged. We previously mutated the SHP-2 gene in mouse embryonic stem (ES) cells. Analyses of in vitro (Qu et al., 1997) and in vivo (Qu et al., 1998) hematopoietic cell differentiation from SHP-2 À/À ES cells demonstrated that SHP-2 was required for primitive hematopoiesis. These results stand in sharp contrast to the negative role of the closely related SHP-1 phosphatase in hematopoietic cell signaling. Indeed, our subsequent genetic analyses of hematopoietic development in the SHP-2/SHP-1 double mutant mice confirmed opposing roles for SHP-2 and SHP-1 in regulating hematopoietic-lineage determination (Qu et al., 2001) .
The detailed biochemical activities of SHP-2 phosphatase in IL-3 signal transduction are not well characterized. In the present study, we generated immortalized SHP-2 À/À mutant hematopoietic cell pools by the retroviral-mediated gene transfer of a homeoboxcontaining gene HOX11 and examined the role of SHP-2 in modulating hematopoietic cell responses to IL-3. Furthermore, catalytic-dependent and -independent activities of SHP-2 in IL-3 signal transduction were investigated using these unique SHP-2 À/À cell pools, as well as the catalytically inactive SHP-2-overexpressing Ba/F3 cell lines.
Results

Immortalization of SHP-2 mutant hematopoietic cells
Further characterization of the molecular mechanisms by which SHP-2 regulates hematopoietic cytokine signal transduction requires the availability of SHP-2 mutant hematopoietic cell lines. As the targeted deletion (amino acids 46-110) in SHP-2 results in a loss-of-function mutation (Qu et al., 1997 (Qu et al., , 1998 Saxton et al., 1997) , SHP-2 À/À embryos die between 8.5 and 10.5 days postcoitum (dpc) with multiple developmental defects in mesodermal patterning. Consequently, the number of hematopoietic cells available from SHP-2 À/À embryos is limited, precluding large-scale biochemical analysis. To circumvent this problem, we sought to establish permanent SHP-2 À/À hematopoietic cell lines through immortalization.
To generate wild-type (WT) and SHP-2 À/À hematopoietic cell lines, 9.0-9.5 dpc yolk sacs were dissected from the embryos produced from timed intercrosses between SHP-2 heterozygous (SHP-2 þ /À ) mice. HOX 11, a homeobox-containing gene that has a strong immortalizing function for hematopoietic precursor cells (Hawley et al., 1994; Yu et al., 2002a) , was used to immortalize yolk sac hematopoietic cells through retroviral-mediated gene transfer. After HOX11 transduction, each yolk sac generated an immortalized cell pool (line) with unlimited growth potential, whereas untransduced cells ceased growing and died after several passages.
Immortalized cell pools were genotyped and identified by PCR for detection of WT and mutant SHP-2 loci in cellular genomic DNA (Qu et al., 1998) . Anti-SHP-2 immunoblotting confirmed that WT SHP-2 was not detected in SHP-2 À/À cells. Instead, a truncated form of SHP-2 corresponding to deletion of amino acids 46-110 was expressed. However, the expression level of this aberrant protein was very low compared to the WT protein ( Figure 1a) , being barely detectable. This result suggests that the deleted sequences encoding the Nterminal region of SHP-2 are required for stabilization of either its mRNA transcripts or protein. Remarkably, the expression level of the truncated form of SHP-2 in the mutant hematopoietic cells is much lower than that detected in SHP-2 À/À ES cells or embryonic fibroblast cells (Qu et al., 1997; Yuan et al., 2003) .
Morphological examination of cytospin samples of the yolk sac hematopoietic cell pools showed that the majority (46 out of 50) of cell pools with various genotypes were composed of homogeneous primitive blast-like cells, most likely multipotential hematopoietic precursor cells, as 80-90% of the cells of every cell pool examined express CD34 and c-kit (data not shown), differing from the heterogeneous phenotypes of the HOX11 immortalized bone marrow (BM) hematopoietic cells (Hawley et al., 1994) . This is presumably because yolk sac is the earliest developing hematopoietic site; most yolk sac cells in this stage are still very early stem/progenitor cells.
IL-3-elicited signal transduction in SHP-2 À/À cells is impaired
Analyses of the growth responsiveness of the cell pools revealed that they were strictly IL-3 dependent (cells died following withdrawal of IL-3 from the medium). We decided therefore to first investigate the role of SHP-2 in IL-3-mediated signal transduction by using these cell pools. Cell pools expressing similar levels of IL-3 Ra and IL-3 Rb (Aic2A and Aic2B) ( Figure 1b) were selected for subsequent biological and biochemical analyses. Although the survival of SHP-2 À/À cells in IL-3-containing medium (2 ng/ml) was not affected (data not shown), the proliferative response of SHP-2 À/À cells to IL-3 was dramatically reduced compared to the WT control. Notably, reintroduction of WT SHP-2 into the mutant cells partially rescued their proliferative responses (Figure 2 ), further confirming an overall positive role for SHP-2 in IL-3 signal transduction.
Next, activation of IL-3 receptor and its downstream pathways in SHP-2 À/À cells were carefully examined. As shown in Figure 3a , in mutant cells lacking SHP-2 phosphatase, IL-3-induced tyrosyl phosphorylation of cellular proteins was significantly reduced. This is in sharp contrast to the elevated tyrosyl phosphorylation response to IL-3 in SHP-1 mutant hematopoietic cells (Yi et al., 1993) , concordant with the notion of opposite roles of these two related tyrosine phosphatases in IL-3-triggered intracellular signaling. Indeed, activation of Erk kinases in SHP-2 À/À cells was greatly reduced (Figure 3b) , and phosphorylation of Akt, a putative downstream target of PI3 kinase, in SHP-2 À/À cells was also decreased (Figure 3c , upper panel). Subsequent PI3 kinase assays confirmed that PI3 kinase activation was diminished in SHP-2 mutant cells ( Figure 3c , lower panel). As Jak2 kinase plays a critical role in IL-3-elicited signal transduction (Watanabe et al., 1996; Neubauer et al., 1998; Parganas et al., 1998) , activation of Jak2 in SHP-2 À/À cells was next determined. Jak2 activation defined by its tyrosyl phosphorylation was significantly decreased in SHP-2 À/À cells ( Figure 3d ). In agreement with this observation, phosphorylation of its downstream target, Stat5, was also diminished.
Tyrosyl phosphorylation of IL-3 Rb, induced most likely by Jak2 kinase, was also suppressed in SHP-2 À/À cells stimulated by IL-3 ( Figure 4a ). Likewise, phosphorylation of the Shc adaptor protein that links the Erk pathway to IL-3 receptor (Bone and Welham, 2000; Gu et al., 2000) was decreased in mutant cells ( Figure 4a ). Consequently, the resulting association between Shc and Grb2 induced by IL-3 was significantly reduced (Figure 4a ). Interestingly, tyrosyl phosphorylation of Gab2, a putative substrate of SHP-2 phosphatase (Gu et al., 1998; Nishida et al., 1999) , and an important intermediary of the PI3 kinase pathway (Gu et al., 2000) , was also abolished (but not elevated) in SHP-2 À/À cells. The association between Gab2 and the residual truncated SHP-2 was undetectable in mutant cells ( Figure 4b ). Defective IL-3 signaling in SHP-2 À/À cells appears to be due to loss of SHP-2 function, since although a residual truncated SHP-2 is expressed, tyrosyl phosphorylation of SHP-2, required for its activation (Vogel et al., 1993) , was not detectable in the mutant cells (Figure 4c ). Furthermore, reintroduction of WT SHP-2 into mutant cells partially restored /well). After 6 days of culture, in the presence of various concentrations of IL-3, cell numbers were determined using the MTS cell proliferation assay. Three to four independent experiments were performed and similar results were obtained in each. Results shown are the mean7s.d. of triplicates from one experiment IL-3-induced signaling ( Figure 5 ). Taken together, these results suggest that an intact, functional SHP-2 is required for optimal IL-3 activation of the Jak/Stat, Erk, and PI3 kinase pathways.
The catalytic activity of SHP-2 is required for IL-3-mediated hematopoietic progenitor cell response Biological and biochemical results obtained from SHP-2 À/À cells demonstrated that SHP-2 was required for optimal responses to IL-3. As SHP-2 deficiency appears to block IL-3 signal transduction at a very early stage, it is unclear whether the phenotype of mutant cells results from the loss of SHP-2 protein or its catalytic activity. To address this issue, biological significance of the enzymatic activity of SHP-2 in IL-3-mediated hematopoietic cell response was next examined. Previous biochemical evidence has demonstrated that the cysteine (C) at position 459 is critical for SHP-2 catalytic activity. Replacement of cysteine with serine (S) at this site completely abolishes its enzymatic activity. When overexpressed, the SHP-2 C459S (SHP-2 C/S) mutant inhibits endogenous SHP-2 function by dominantnegative inhibition of the catalytic activity of SHP-2 and/or trapping its substrates. This mutant has been widely used to study SHP-2 function in cell signaling (Bennett et al., 1996; Maegawa et al., 1999; Manes et al., 1999; Inagaki et al., 2000) . We transduced primary BM cells with SHP-2 C/S. Transduced marrow cells were sorted by FACS based on green fluorescent protein (GFP) expression and then assayed for their differentiation capacity in response to IL-3. The protein expression level of SHP-2 C/S was approximately four times higher than endogenous SHP-2 in the vector control-transduced BM cells (Figure 6a ). Hematopoietic colony forming efficiency of SHP-2 C/Stransduced BM cells in methylcellulose medium supplemented with a full combination of hematopoietic growth factors (see Materials and methods) or with IL-3 alone was markedly reduced compared to that of GFP vectortransduced cells (Figure 6b) . Likewise, the expansion (due to differentiation and proliferation) rate of SHP-2 C/S-transduced BM cells in IL-3-containing liquid culture was decreased by 62% (Figure 6c ), demonstrating that the catalytic activity of SHP-2 is indeed required for IL-3-induced hematopoietic cell differentiation and proliferation.
Catalytic-dependent and -independent roles of SHP-2 in IL-3 signaling Since SHP-2 catalytic activity is important for IL-3-mediated cellular responses, we next sought to define how the enzymatic activity of SHP-2 contributes to IL-3 signal transduction. Ba/F3 cells, an IL-3-dependent murine hematopoietic cell line, were transduced with SHP-2 C/S or the GFP control vector. Stable clones overexpressing SHP-2 C/S were selected by limiting dilution of sorted cells. The expression level of SHP-2 C/S in the stable clones was four times higher than that of endogenous SHP-2 ( Figure 7a) . As a consequence of interfering with endogenous SHP-2 function, proliferation of SHP-2 C/S-overexpressing cells was decreased at lower doses of IL-3 (Figure 7b ). Consistent with this observation, activation of Erk kinases was reduced in magnitude and duration in C/S-overexpressing cells (Figure 7c ), demonstrating an important role for the catalytic activity of SHP-2 in IL-3-stimulated Erk activation. Similarly, tyrosyl phosphorylation of Jak2 in response to IL-3 stimulation was also significantly decreased in the SHP-2 C/S expressing cells (Figure 7d) . Interestingly, the PI3 kinase pathway did not appear to be affected by the catalytically inactive mutant SHP-2, because serine phosphorylation of Akt kinase was comparably induced in SHP-2 C/S-overexpressing cells (Figure 7e) . These results together suggest that SHP-2 plays differential roles in the IL-3-induced Jak/Stat, Erk, and PI3 kinase pathways in catalytic-dependent and -independent manners.
Since SHP-2 catalytic activity is important for IL-3-induced Erk activation, we next focused on the involvement of SHP-2 in the Erk pathway, particularly the proximal signaling events downstream of IL-3 Rb. Tyrosyl phosphorylation of Shc was significantly reduced in SHP-2 C/S-transduced cells, consistent with the observation that Jak2 activation was decreased by overexpression of SHP-2 C/S (Figure 7d ). Protein-protein interaction analyses revealed that the amount of Grb2 detected in the anti-Shc immunocomplex was markedly reduced in SHP-2 C/S-transduced cells (Figure 8a ). Since the N-terminal SH3 domain of Grb2 constitutively associates with Sos, the guanine nucleotide exchange factor that activates Ras and consequently the rest of the MAP kinase pathway, the level of Sos protein detected in the anti-Shc immunocomplex was also decreased. Reciprocally, the amount of tyrosyl-phosphorylated Shc detected in the anti-Sos complexes was consistently reduced in SHP-2 C/S-overexpressing cells (Figure 8b ). By contrast, the constitutive association between Sos and Grb2 in SHP-2 C/S cells was not changed. These results indicate that the amount of the Grb2/Sos complex recruited to phosphorylated Shc following IL-3 stimulation was inhibited by overexpression of the catalytically inert SHP-2, thereby leading to a decrease in the activation of the Erk pathway.
Notably, although the signal flow is decreased along the Shc-Grb2-Sos-Erk pathway, tyrosyl phosphorylation of the Gab2 adaptor protein was dramatically enhanced in Control and two independent SHP-2 C/S clones were seeded in triplicate into wells of a 96-well plate (1 Â 10 4 cells/well). After 3 days in culture, in the presence of various concentrations of IL-3, cell numbers were determined using the MTS cell proliferation assay. Results shown are the mean7s.d. of triplicates from one of two independent experiments. SHP-2 C/S-overexpressing cells were starved and stimulated with IL-3 (2 ng/ml) for the indicated time periods. Whole cell lysates were prepared and examined for Erk (c), Jak2 (d), and Akt (e) activation. Blots were stripped and reprobed with anti-Erk, antiJak2, and anti-Akt Abs to examine protein loading. Representative results of two to three independent experiments are shown SHP-2 C/S-overexpressing cells (Figure 8c) , concordant with the model that Gab2 is a downstream target of SHP-2 phosphatase (Gu et al., 1998; Nishida et al., 1999) . More importantly, since Grb2 binding to Shc is decreased, these data suggest that in addition to the Grb2/Gab2 association, Gab2 might be recruited to IL-3 Rb and become tyrosyl phosphorylated through other pathway(s).
Discussion
In this report, we have presented several novel results important for understanding the function of SHP-2 tyrosine phosphatase in hematopoietic cell signaling. First, we established immortalized SHP-2 mutant hematopoietic cell pools. Using the SHP-2 À/À cell pools, we demonstrated that SHP-2 plays an important role in IL-3 signaling. IL-3-initiated signal transduction was severely impaired by the SHP-2 mutation. Second, SHP-2 catalytic activity was demonstrated to be required for IL-3-induced differentiation and proliferation of primary hematopoietic progenitor cells. Third, SHP-2 was shown to act at multiple points in the IL-3 signaling pathways, functioning in both enzymatic activity-dependent and -independent manners. Although intact SHP-2 protein is required for IL-3-induced activation of all downstream pathways examined, its catalytic activity appears to be only important to the Jak/Stat and Erk, but not the PI3 kinase pathways. Whole cell lysates were prepared and immunoprecipitated with anti-Shc (a), anti-Sos (b), and anti-Gab2 (c) Abs followed by anti-PY immunoblotting. Blots were then stripped and reimmunoblotted with anti-Grb2, anti-Sos, anti-SHP-2, anti-Shc, and anti-Gab2 Abs to examine protein-protein associations and protein loading. Representative results from two to four independent experiments are shown Derivation of immortalized SHP-2 À/À hematopoietic cell pools Dissecting the molecular mechanisms by which SHP-2 regulates hematopoietic cell signaling requires SHP-2 mutant hematopoietic cell lines. Immortalized SHP-2 À/À hematopoietic cell pools generated in this study would thus facilitate investigations of the involvement of SHP-2, the consequences of loss of its function, and the significance of its catalytic activity in hematopoietic cell regulation. Although our targeted mutation of the SHP-2 gene generated an in-frame, N-terminal deletion of SHP-2 (Qu et al., 1997; Saxton et al., 1997) , it appears to act as a loss-of-function of mutation, since reintroduced WT SHP-2 in the mutant cells partially restored IL-3-induced signaling and cellular responses (Figure 2 and 5). Moreover, the truncated form of SHP-2 is hardly detectable in SHP-2 À/À hematopoietic cell pools ( Figure  1a and 4c) , and tyrosyl phosphorylation of the truncated SHP-2 and its interactions with other signaling molecules examined were also undetectable.
SHP-2 functions at multiple points in the IL-3-induced signaling pathway
SHP-2 appears to be involved in IL-3 signal transduction in multiple ways. This notion is supported by comparison of IL-3 signaling in SHP-2 À/À and SHP-2 C/S-overexpressing cells. Although SHP-2 apparently functions downstream of IL-3 signaling, it also plays an important role in the initiation of the IL-3 signal. In SHP-2 À/À cells, IL-3 signaling is blocked at a very early step. In contrast to the SHP-2 À/À mutation, overexpression of catalytically inactive SHP-2 only disturbs the catalytic activity of endogenous SHP-2. Its capacity for protein-protein interactions is retained. Therefore, more severe signaling defects were observed in SHP-2 À/À cells than in the SHP-2 C/S-overexpressing cells. This also explains why tyrosyl phosphorylation of Gab2, a putative substrate of SHP-2 phosphatase (Gu et al., 1998; Nishida et al., 1999) , was abolished in SHP-2-deficient cells (Figure 4b ), whereas IL-3-induced Gab2 phosphorylation in SHP-2 C/S-overexpressing Ba/F3 cells was dramatically enhanced (Figure 8c) . Since previous studies have demonstrated that SHP-2 binds to IL-3 Rb upon IL-3 stimulation (Bone et al., 1997; Itoh et al., 1998) , SHP-2 might initiate part of signal transduction from IL-3 receptor by coupling the downstream signaling complexes to the receptor. In the absence of SHP-2 protein, transduction of IL-3-induced signal is diminished at this initial step. This notion is also supported by previous proposals that SHP-2 might serve as an adaptor in PDGF receptor (Bennett et al., 1994; Li et al., 1994) and TCR (Frearson and Alexander, 1998) signaling.
Reintroduction of WT SHP-2 into mutant cells partially restored IL-3-induced signaling ( Figure 5 ) and cellular proliferative response to IL-3 (Figure 2 ). The rescue data further support the overall positive role of SHP-2 in IL-3 signaling, even though the rescue effect was not complete. The partial recovery of IL-3 responsiveness in the rescued cells might be because the expression level of reintroduced SHP-2 is not as high as WT SHP-2 in the control cells ( Figure 5 ). Additionally, it remains possible that the mutant yolk sac cells used for immortalization have developed in the absence of SHP-2 and might be intrinsically different to the WT cells.
Catalytic-dependent and -independent functions of SHP-2 in IL-3 signaling
In addition to its adaptor function in the initial transmission of IL-3 signaling, SHP-2 also acts further downstream of the IL-3 signaling pathways. Activation of Jak2 kinase was significantly reduced by overexpression of SHP-2 C/S (Figure 7d) . As a result of the decrease in Jak2 activation, tyrosyl phosphorylation of Shc, and therefore the binding of the Grb2/Sos complex to Shc, were reduced ( Figure 8a) . Consequently, the signal flow to Erk kinases is decreased in SHP-2 C/Soverexpressing cells (Figure 7c) . As the precise mechanism of IL-3-induced Jak2 activation is still unclear, the biochemical basis of SHP-2 action in this context remains to be further determined. Since its catalytic activity is important in Jak2 activation, it is possible that SHP-2 promotes Jak2 activation by dephosphorylation of an as yet unknown Jak2 inhibitor(s).
Interestingly, the enzymatic activity of SHP-2 is dispensable for IL-3 induction of the PI3 kinase pathway. The role of SHP-2 phosphatase in growth factor-induced PI3 kinase pathways varies, depending on the stimulus and its intracellular signaling mechanisms. SHP-2 plays negative or positive roles in EGF and IGF-1-induced PI3 kinase activation, respectively, while PDGF-induced PI3 kinase activation was not affected by loss of SHP-2 function (Zhang et al., 2002) . We provide evidence in this report that in IL-3 signaling, although phosphatase activity of SHP-2 was redundant for PI3 kinase activation, an intact SHP-2 protein was indeed required (Figure 3c ), suggesting that SHP-2 facilitates IL-3-induced PI3 kinase activation as an adaptor protein.
It is not clear at this point as to how SHP-2 functions as an adaptor protein to promote IL-3-induced PI3 kinase pathway. Many cytokine receptors such as IL-3 Rb, Flt3, and IL-2 receptor b chain lack the binding site for the p85 subunit of PI3 kinase Zhang and Broxmeyer, 1999) , even though the PI3 kinase pathway can be activated by these receptors. It has recently emerged that the adaptor protein Gab2 mediates activation of the PI3 kinase pathway by association with p85 (Wickrema et al., 1999; Gu et al., 2000; Miyakawa et al., 2001) . Since SHP-2 can directly bind to Y612 and perhaps other tyrosine residues on IL-3 Rb (Bone et al., 1997; Itoh et al., 1998) as well as Gab2 (Figure 8c) (Gu et al., 1998; Nishida et al., 1999) , it is likely that SHP-2 mediates IL-3-induced PI3 kinase activation by coupling the Gab2/p85 complex to the proximity of IL-3 Rb. If this is the case, disruption of the interactions between SHP-2 and IL-3 Rb, Gab2, or p85 would repress IL-3 activation of PI3 kinase.
Experiments testing this hypothesis are currently ongoing in our laboratory.
Materials and methods
Mice, cell lines, and reagents
SHP-2
þ /À mice were housed at the American Red Cross Vivarium. All animal procedures complied with the NIH Guide for the Care and Use of Laboratory Animals. Ba/F3, a murine pro-B lymphoma cell line was routinely maintained in RPMI-1640 medium with 0.2 ng/ml recombinant mouse IL-3 plus 10% fetal bovine serum (FBS). Biotin-labeled anti-IL-3 Ra Ab and PE-labeled anti-IL-3 Rb immunostaining Ab were purchased from BD Biosciences (San Diego, CA, USA). Anti-SHP-2, anti-IL-3 Rb, anti-Grb2, anti-Sos, anti-Stat5, anti-Erk, and anti-phospho-Erk antibodies (Abs) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antiphospho-tyrosine (PY) (4G10), anti-Jak2, anti-Shc, and antip85 subunit of PI3 kinase Abs were supplied by Upstate Biotechnology (Lake Placid, NY, USA). Anti-phospho-Akt and anti-Akt Abs were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-Gab2 Ab was provided by Dr Gen-Sheng Feng (Burnham Research Institute, La Jolla, CA, USA). The MTS cell proliferation assay kit (a colorimetric method for determining viable cells) was obtained from Promega Life Science (Madison, WI, USA).
Immortalization of SHP-2
À/À hematopoietic cells Embryos (9.0-9.5 dpc) from intercrosses between SHP-2 þ /À mice were carefully dissected. Yolk sacs were harvested and rinsed with a large volume of PBS, and then dissociated into single cells by passing through 22 gauge needles. Single yolk sac cells were prestimulated with IL-3 (20 ng/ml), SCF (50 ng/ ml), and IL-6 (50 ng/ml) for 24-48 h before being transduced with MSCVhyg-HOX11 retroviruses (Hawley et al., 1994; Yu et al., 2002a) . Transduced cells were maintained in IL-3 (2 ng/ ml) and 10% FBS-containing RPMI 1640 medium. Immortalized yolk sac cell pools were genotyped for SHP-2 gene status using PCR to detect mutant and WT loci in genomic DNA (Qu et al., 1998) .
Immunoprecipitation and immunoblotting
Cells were lysed in RIPA buffer (50 mm Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mm NaCl, 1 mm EDTA, 1 mm NaF, 2 mm Na 3 VO 4 , and 1 mm PMSF). Whole cell lysates (500 mg) were immunoprecipitated with 1-2 mg purified Abs or 2 ml antiserum Abs. Immunoprecipitates were washed three times with HNTG buffer (20 mm HEPES pH 7.5, 150 mm NaCl, 1% Glycerol, 0.1% Triton X-100, and 1 mm Na 3 VO 4 ) and resolved by SDS-PAGE followed by immunoblotting with the indicated Abs.
PI3 kinase assay
Cell lysates (500 mg) were immunoprecipitated with anti-p85 Ab. PI3 kinase activity in the immunocomplex was determined by measuring its ability to catalyse the formation of phosphatidylinositol (PI) 3 phosphate from PI as previously described (Qu et al., 1999; Yu et al., 2002b) .
Generation of a catalytically inactive SHP-2 retroviral producer cell line and transduction of primary BM hematopoietic stem/ progenitor cells
Catalytically inactive SHP-2 (SHP-2 C459S) cDNA (Zhao et al., 1995) was cloned into the MSCV-IR-GFP retroviral vector (Figure 6a ) (Persons et al., 1999) containing an internal ribosomal entry sequence (IRES) driving the expression of a downstream GFP gene to facilitate tracking of transduced cells. Ecotropic GP þ E-86-based retroviral producer cell lines were generated by transduction with retroviral supernatant produced by 293T cells that were transiently cotransfected with pQEPAM3 (Minus E) packaging plasmid, pSraG (VSV-G) envelope plasmid and the recombinant retroviral plasmid.
To transduce primary hematopoietic stem/progenitor cells with SHP-2 C/S, nucleated BM cells harvested from femurs of 4-week-old WT mice were prestimulated in RPMI-1640 medium containing 10% FBS, SCF (50 ng/ml), IL-3 (20 ng/ ml), and IL-6 (50 ng/ml) for 2 days, and then cocultured with irradiated (1500 rad) retroviral producer cells in the presence of polybrene (6 mg/ml) for 48 h. Transduced cells were sorted by FACS based on GFP expression.
Hematopoietic progenitor differentiation assay
BM cells (2.5 Â 10 4 cells/ml) were assayed for colony-forming units (CFUs) in 0.9% methylcellulose IMDM medium containing 30% FBS, glutamine (10 À4 m), b-mercaptoethanol (3.3 Â 10 À5 m), and a combination of hematopoietic growth factors (5% pokeweed mitogen-stimulated spleen cell conditioned medium, 20 ng/ml IL-3, 50 ng/ml SCF, 2 U/ml EPO, and 0.1 mm hemin) (Qu et al., 1998; Yu et al., 2002b) . After 7 days of culture at 371C in a 5% CO 2 incubator, hematopoietic cell colonies were counted under an inverted microscope.
